Mostrar el registro sencillo del ítem

dc.contributor.author
Ceaglio, Natalia Analia  
dc.contributor.author
Oggero Eberhardt, Marcos Rafael  
dc.contributor.other
Calzada, Victoria  
dc.contributor.other
Cerecetto, Hugo  
dc.contributor.other
Tosar, Juan Pablo  
dc.date.available
2025-08-13T11:32:36Z  
dc.date.issued
2025  
dc.identifier.citation
Ceaglio, Natalia Analia; Oggero Eberhardt, Marcos Rafael; Development and production of protein-based biotherapeutics in mammalian cells; Springer Nature Switzerland AG; 2025; 65-122  
dc.identifier.isbn
978-3-031-81025-1  
dc.identifier.uri
http://hdl.handle.net/11336/268835  
dc.description.abstract
Mammalian cell-derived biotherapeutics have revolutionized the treatment of various diseases, with antibodies, fusion proteins, and cytokines being their most significant successes. The so-called innovative or original products, bio-similars, and biobetters have been central pieces of this evolution, alongside the increased capacity of bioprocesses to produce them with better yields and quality. This upward trend, where Chinese hamster ovary cells represent the workhorses for large-scale production of biotherapeutics, has led to a profound and substantial generation of knowledge, methodologies, and tools applied to research, development, and innovation. Protein-biotherapeutical production is a complex bioprocess that involves a wide range of techniques, ranging from genetic engineering, followed by upstream and downstream stages up to the final product. In this chapter, we will succinctly outline the key stages to carry out successful bioprocesses with emphasis in increasing productivity and to select the appropriate methods for producing a protein for therapy. A final section, related to the modification of existing protein-biologics to improve their properties, is included aiming to generate biobet-ters or second-generation biotherapeutics. A brief description of glycoengi-neering approaches gives interesting clues to design novel long lasting bio-drugs. The main objective of the chapter is contributing to enhance the pro-duction processes of diverse biotherapeutical proteins for the economically and industrially important sector of biologics.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer Nature Switzerland AG  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
PROTEIN-BIOTHERAPEUTICS  
dc.subject
MAMMALIAN CELLS  
dc.subject
BIOPROCESSES  
dc.subject
UPSTREAM  
dc.subject
DOWNSTREAM  
dc.subject.classification
Otras Ciencias de la Salud  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Development and production of protein-based biotherapeutics in mammalian cells  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/bookPart  
dc.type
info:ar-repo/semantics/parte de libro  
dc.date.updated
2025-08-12T12:53:06Z  
dc.journal.pagination
65-122  
dc.journal.pais
Suiza  
dc.journal.ciudad
Cham  
dc.description.fil
Fil: Ceaglio, Natalia Analia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina  
dc.description.fil
Fil: Oggero Eberhardt, Marcos Rafael. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/chapter/10.1007/7355_2024_168  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/7355_2024_168  
dc.conicet.paginas
355  
dc.source.titulo
Biotherapeutics: From small to large molecules and cells